Splenopentin

The verdict

Our read at a glance.

Whether the small historical splenopentin/SP-5 literature supports any modern claim beyond identity, immune-cell biology, preclinical models, and limited analog-context human evidence.

The signal

The literature here is thin, so this memo rests on a smaller source set than the usual 40-source threshold. The direct source base includes identity anchors, one direct review, foundational splenin/thymopoietin biology, human ex vivo immune-cell work, a few limited historical human or analog-context records, and animal immune models. That is not enough to establish treatment benefit or product safety.

The unknown

Whether any signal would remain clinically meaningful under modern standards after separating exact splenopentin from Berlopentin, BCH 069, DAc-SP5, thymopentin, tuftsin, thymic/splenic extracts, and internet-market products.

Our read

Source-scarce and high uncertainty. Splenopentin belongs on the safety/regulatory watch because it is a defined peptide with a real historical literature, but the evidence is too small, old, and analog-heavy to support immune, allergy, psoriasis, infection-prevention, radiation-recovery, cancer, life-extension, wellness, or product-use claims.